Background: Lubricin and hyaluronic acid lubricate articular cartilage and prevent wear. Because lubricin loss occurs after anterior cruciate ligament injury, intra-articular lubricin injections may reduce cartilage damage in the anterior cruciate ligamentdeficient knee.
Anterior cruciate ligament (ACL) injury is associated with a high prevalence of posttraumatic osteoarthritis (OA), the rate of which appears not to be reduced after the current gold standard of treatment, surgical ACL reconstruction. 38, 42 In humans, cartilage loss associated with OA occurs over the course of years, a process stimulated by cytokines and degradative enzymes produced by the synovium and chondrocytes. 2, 40, 43, 48 The role of mechanical stress in perpetuating the progression of OA is not completely understood, but altered joint mechanics and subsequent cartilage wear are thought to contribute to the onset of OA in these patients. 13, 51 It remains unknown whether the development of OA after ACL injury is initiated because of inflammation, cartilage impact, abnormal contact biomechanics, or a combination thereof.
In healthy synovial joints, the articular surfaces serve as an extremely low-friction bearing. The integrity of this bearing is protected by multiple lubrication methods, which depend on synovial fluid composition as well as cartilage matrix structure. # Inadequate cartilage surface lubrication attributable to the acute inflammatory destruction of lubricin (LUB) has been proposed as 1 likely mechanism linking acute joint injury to subsequent OA. This hypothesis is supported by previous studies that have shown that synovial fluid LUB levels are decreased in patients with recent ACL injury, 11 and that this decrease is associated with short-term increases in cytokine levels and long-term increases in cartilage damage after ACL transection in experimental models. 12, 56 An unanswered question is whether preserving or supplementing the joint lubricating mechanisms after ACL injury will slow or halt the progression of posttraumatic OA in these patients.
Intra-articular injections of hyaluronic acid (HA) and, more recently, LUB have been proposed as 2 possible means to prevent OA progression by enhancing the lubricating ability of synovial fluid after injury. 53 Hyaluronic acid contributes to the viscosity of synovial fluid so that it can act as a cushion and stabilizer for hydrodynamic lubrication, 26, 31, 39 and thus could provide chondroprotection by preventing wear. In vitro, HA has also been reported to modulate the expression of inflammatory cytokines 41 and stimulate chondrocytes to synthesize matrix proteins and proteoglycans, which could slow disease progression, 6, 17 but animal models are not in agreement as to whether HA delays, 1, 49 accelerates, [15] [16] or has no effect on cartilage damage. 52 Despite the limited evidence for disease-modifying effects in vivo, several clinical studies have been performed to determine whether the use of intra-articular HA reduces pain and increases joint motion in the shoulder, 5 hip, 46 and ankle, 59 and in the knee after meniscectomy and ACL reconstruction. 19, 20 Intra-articular injections of HA are currently approved for the treatment of pain associated with knee OA since analgesia is maintained for up to several months after injection. 6, 17 However, it is unknown if any of the reported clinical effects of HA in reducing pain symptoms correlate with long-term chondroprotection.
Lubricin is a mucinous glycoprotein that is highly glycosylated with O-linked Gal(b1-3)-GalNAc-NeuAc in its central mucin domain. 45, 55 This protein is configured to form a discontinuous nanofilm that exerts repulsive forces and is the basis for its antiadhesive and lubricating properties when bound to the cartilage surface. 45 Flannery et al 14 have reported short-term chondroprotective effects using the rat meniscectomy model after treatment with recombinant LUB. Jones et al 28 also found that in cartilage explants with an intact articular surface, injurious compression resulted in elevated surface friction accompanied by increased chondrocyte LUB expression, suggesting a possible compensatory response.
Given that LUB and HA are both thought to contribute to the lubrication of the articular surface in normal synovial joints, the objective of this study was to determine whether supplementing the synovial fluid of an ACL-deficient knee with LUB and/or HA would reduce cartilage damage 6 weeks after injury in the rat model. The hypotheses were that (1) intra-articular supplementation of LUB will reduce cartilage damage after ACL transection when compared with those treated with a sham injection, (2) intra-articular supplementation of HA will reduce cartilage damage when compared with the sham-treated animals, and (3) intra-articular supplementation of LUB plus HA will further reduce cartilage damage when compared with sham-treated animals or those treated with HA or LUB in isolation. Cartilage damage was assessed using radiographic and histological analyses, and served as the primary outcome measure. In addition, biomarkers of articular cartilage metabolism in synovial fluid were also evaluated after 6 weeks. The synovial fluid biomarkers included indicators of cartilage degradation (sulfated glycosaminoglycan [sGAG], type II collagen [CTX-II]), joint inflammation (interleukin-1b [IL-1b], tumor necrosis factor-a [TNF-a]), and LUB.
METHODS

Experimental Design
After the study received Institutional Animal Care and Use Committee approval, 36 male Lewis rats, 3 months of age, underwent unilateral surgical transection of the ACL of the right knee joint. The rat ACL transection model has been previously characterized and implemented to assess cartilage damage after traumatic knee injury. 12, 18 These animals were randomized after surgery to 1 of 4 intra-articular injection treatment groups: (1) 40 mL phosphate-buffered saline (PBS; sham), (2) 40 mL 3.33 mg/mL high molecular weight HA (Healon, Advanced Medical Optics, Upsala, Sweden), (3) 40 mL 200 mg/mL purified human LUB, or (4) 40 mL 200 mg/mL LUB with 3.33 mg/mL HA (LUB1HA). There were 9 animals in each treatment group. Within all treatment groups, the injections of the ACL-transected knee were initiated 1 week after surgery, and performed twice weekly for 4 weeks. Both knees from each animal were harvested 1 week after the series of injections were completed. The total time from surgery to harvest was 6 weeks. After euthanasia with carbon dioxide gas, serum samples and synovial fluid lavages were obtained from both knees of each animal. Anteroposterior and lateral radiographs were taken of each knee using a high-resolution (14-bit) radiography system (MX-20, Faxitron, Wheeling, Illinois). The images were obtained at 28 kV, with adjustments in kilovolts as needed, to obtain adequate penetration and image quality. Coronal sections from each knee were then obtained for histologic analysis of cartilage degeneration.
Anterior Cruciate Ligament Transection Procedure
Animals were sedated before surgery with an intraperitoneal injection of ketamine (75 mg/kg) and metomidine (0.5mg/kg). Subcutaneous buprenorphine (0.03 mg/kg) was given immediately after surgery and twice daily for 3 days to provide postoperative analgesia. After the animal was anesthetized, the operative knee was shaved and prepared using an iodine solution and alcohol. The limb was sterilely draped with the animal supine. A 1-cm midline incision was made over the anterior knee and the skin was mobilized to expose the patellar tendon. A medial parapatellar incision was made to open the joint capsule. To expose the notch, the patella was subluxated laterally, rather than everted, to avoid additional damage to the articular cartilage. With the knee in flexion, the ACL was carefully sectioned with the tip of a scalpel. Complete ACL transection was confirmed by manually testing the joint for anterior laxity. The peripatellar capsular incision was then closed using 4-0 Vicryl sutures (Ethicon, Somerville, New Jersey). The skin was closed with staples. Postoperatively, animals were allowed to bear weight as tolerated.
Intra-articular Injections
Before we performed the intra-articular injections, anesthesia was induced in a chamber with 5% isoflurane. Once anesthetized, the animal was placed supine with its nose set in a cone and dosed with 2% isoflurane to maintain anesthesia. The knee was shaved and prepared to provide a sterile field. Intra-articular injections were then performed through the patellar tendon with the knee in flexion using a 3/10 mL, 29-gauge pediatric insulin syringe. Intra-articular placement of the injection was confirmed by the lack of resistance to flow with injection and by feeling the distention of the knee joint capsule medial to the patellar tendon.
Purified LUB Preparation
Human synovial fluid LUB was purified from synovial fluid samples that were obtained at the time of total knee arthroplasty as previously described. 25 The synovial fluid samples for making the purified human LUB were obtained under an Institutional Review Board-approved protocol. After joint aspiration, samples were centrifuged at 10 000g at 4°C for 1 hour to remove cellular debris. The processed samples were pooled and stored at -20°C.
To obtain purified LUB, the human synovial fluid was filtered through 0.22-mm sterile filter units (Nalgene, Rochester, New York) at 4°C over 2 days. The retentate was scraped off the filter membranes and resuspended with 50 mM NaAc buffer, pH 5.5, containing proteolytic inhibitors, to the original synovial fluid volume. Digestion of HA was then carried out with Streptomyces hyaluronidase (Sigma, St Louis, Missouri), 1 U/mL of resuspended synovial fluid at 37°C for 18 hours. The digest was loaded onto diethylaminoethyl (DEAE) agarose, washed with 50 mM NaAc, and eluted with 1 M NaCl. Eluate was concentrated and dialyzed against polyethylene glycol in 25 mM PBS at pH 7.4, containing 0.5 mM CaCl 2 . The DEAE-bound eluate was fractionated on a peanut agglutinin (PNA)-agarose affinity column with a settled bed volume of 25 mL, equilibrated at room temperature with 25 mM PBS (pH 7.4). Prepurified LUB was maximally eluted in the presence of a step-wise gradient of 0.15 M alactose in 25 mM PBS (pH 7.4). After dialysis against PBS, contaminating fibronectin was removed by a monoclonal antibody directed against human fibronectin (Zymed Laboratories, San Francisco, California) immobilized on Actigel ALD agarose (Sterogene Bioseparations, Arcadia, California). 25 Final purity of the LUB with this method has been found to be greater than 95% by comparing the enzyme-linked immunosorbent assay (ELISA) recovery using a LUB-specific Ab and 280-nm absorbance. 21 Harvest/Specimen Collection After euthanasia, blood samples were obtained by intracardiac aspiration. The samples were centrifuged at 10 000g at 4°C for 20 minutes to remove cellular debris. The aliquots of serum were then frozen at -80°C. After harvest, each hindlimb was disarticulated, the skin removed, and 100 mL of isotonic saline was injected intra-articularly into the knee joint. The knee was manually cycled through flexion and extension ten times to distribute the fluid throughout the joint. The fluid was then aspirated from the joint and frozen at -80°C.
Radiographic Scoring
Radiographs were scored using a modification of the Kellgren-Lawrence scoring system. 32 The Kellgren-Lawrence score for knee OA, as originally described, assigns a score from 0 to 4 based on severity of disease in human subjects. In this study, the scoring was performed on rat knees. Although there are some anatomical differences between rats and humans, the images were scored relative to control radiographs taken of the nonoperative contralateral limb. Radiographs were scored by an orthopaedic surgeon who specializes in adult joint reconstruction with over 30 years of clinical experience treating advanced OA and a third-year orthopaedic surgery resident. Both examiners were blinded to the animal number and treatment group when scoring. The respective scores of both examiners for each animal were averaged for analysis.
Quantification of sGAG, CTXII, IL-1b, TNF-a, and LUB
The sGAG concentrations, a marker of proteoglycan turnover, in the synovial fluid lavages of the ACL-transected joints were measured using Alcian blue dye-binding assay (Alpco Diagnostics, Windham, New Hampshire). 4 The assay is based on the formation of an insoluble blue-colored complex between sGAG and Alcian blue, which can be quantified by absorbance at 590 nm. The sGAG concentrations were determined using serially diluted chondroitin-6 sulfate as a standard. Synovial fluid lavage CTXII levels, a marker of collagen II breakdown, were measured using serum preclinical Cartilaps ELISA (Immunodiagnostic Systems, Fountain Hills, Arizona). The presence of inflammatory cytokines (TNF-a and IL-1b) in the synovial fluid lavages was quantified using commercially available ELISA kits (Invitrogen, Carlsbad, California). The reported minimum detection limits for TNF-a and IL-1b assays are 0.3 and 0.1 pg/mL, respectively.
The LUB concentrations in synovial fluid lavages were quantified with a sandwich ELISA using PNA (EY Laboratories, San Mateo, California) and monoclonal antibody 9G3 as previously decribed. 12 This antibody is specific for the LUB mucin domain, which is highly conserved across both humans and rats. High-binding 96-well plates (Costar, Cole-Parmer, Vernon Hills, Illinois) were coated overnight with PNA in 50 mM sodium bicarbonate buffer, pH 9.5, at a final concentration of 10 mg/mL. After 24 hours, serial dilutions of purified human LUB and diluted lavaged synovial fluid samples were incubated on the PNA-coated plates for 60 minutes at room temperature; PBS plus 0.1% Tween 20 was then used to wash the plates. Monoclonal antibody 9G3 was added at 1:10 000 dilution and incubated for 60 minutes at room temperature, followed by a second washing with PBS plus 0.1% Tween 20. Peroxidaseconjugated goat anti-mouse immunoglobulin G (IgG) (1:1000 dilution; Invitrogen) was added to the plate for 60 minutes, followed by washing with PBS plus 0.1% Tween 20 and then with PBS alone. Finally, tetramethylbenzidine reagent (Pierce, Rockford, Illinois) was added, and the absorbance was measured at 450 nm.
Normalization to Urea
Because lavages with PBS were required to obtain the synovial fluid samples from the rat knees, the concentrations of the biomarkers were adjusted using the dilution factor established by comparing the concentrations of urea in both the serum and synovial fluids. 33 Urea enters the joint by passive diffusion and is therefore in equilibrium between the serum and synovial fluid. It is not produced or broken down within the joint, and so it has been used to correct for the dilutional effects of a lavage on joint effusions of variable volume when direct aspiration of synovial fluid is not possible. 33 The concentrations of urea in the synovial fluid lavages and serum were measured using a commercially available kit (Bioassay Systems, Hayward, California).
Histology
The joints were processed for histologic analysis by removing the soft tissues from the femur and tibia, while leaving the knee joint capsule intact to facilitate fixation. The specimens were immersed in 10% formalin for a minimum of 72 hours, and then decalcified in Richman-Gelfand-Hill solution. After the proximal femur and distal tibia were removed, the knee joints were embedded in a single block of Paraplast X-tra (Fisher, Santa Clara, California) using a Tissue-Tek VIP 1000 tissue processor (Model #4617, Miles, Elkhart, Indiana). The blocks were trimmed to produce coronal sections for the assessment of articular cartilage integrity in the weightbearing regions of the tibial plateau using a rotary microtome (Model #2030, Reichert-Jung, Vienna, Austria). The samples were sectioned 6 mm thick, mounted on slides, and stained with safranin O/fast green. 47 The slides were viewed and photographed under light microscopy at 403. Osteoarthritis Research Society International (OARSI) scores 44 were assigned by 4 experienced independent examiners who were blinded to the treatment group. After independent scoring, the slides and scores were reviewed by the group, who were still blinded, in an effort to obtain consensus and a representative score.
The scores for the tibial medial and lateral plateaus were averaged for each specimen for statistical analysis.
Statistics
Statistical analyses were performed using 2-way analyses of variance with factors representing the main effects of LUB and HA and their interaction. The Fisher least significant difference was used to perform pair-wise comparison among treatment conditions (sham, HA, LUB, LUB1HA). Primary and secondary outcome measures were the average medial and lateral compartment OARSI scores for the tibial surface for each specimen, the modified Kellgren-Lawrence score, and the synovial fluid lavage concentrations of sGAG, CTXII, IL-1b, TNF-a, and LUB in synovial fluid lavages at the time of harvest. All biomarker comparisons were performed on the urea-adjusted concentrations. Because the Kellgren-Lawrence and OARSI scores represent ordinal outcomes, the 2-way analyses of variance for these outcomes were performed nonparametrically based on a rank transformation prior to analysis. Based on this sample size, this study was 80% powered to detect an effect size of 0.96 for all outcome measures. All statistical analyses were performed using SAS statistical software Version 9.0 (SAS Institute, Cary, North Carolina).
RESULTS
Gross Observations
A return to equal weightbearing on the hindlimbs was observed within 1 week of surgery in all animals. No animals were lost after surgery or postoperative treatment injections.
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After harvest, it was noted that all ACL-transected knees had a positive manual anterior drawer on examination.
Light Microscopy
The mean OARSI scores were greatest in the saline-and HA-treated groups, and lower in the LUB-and LUB1HAtreated groups (Figure 1 ). Relative to PBS, HA treatment resulted in a 9% higher mean OARSI score, while LUB and LUB1HA reduced the mean OARSI score by 15% and 32%, respectively. All groups showed some evidence of cartilage damage that included surface fibrillation, hyperand hypocellularity, and loss of proteoglycan staining (Figure 2) . The joints treated with LUB had significantly lower OARSI histology scores than saline-or HA-treated knees (P = .015). There was no evidence that the addition of HA produced changes in OARSI scores (P = .51), nor did HA significantly influence the effect of LUB (P = .37).
Radiographs
The modified Kellgren-Lawrence scores were highest in the saline-and HA-treated joints, and were significantly lower in the LUB-and LUB1HA-treated joints (P = .039; Figures 3 and 4 ). Relative to PBS, HA treatment resulted in a 14% lower modified Kellgren-Lawrence score, while LUB and LUB1HA each reduced the mean score by 38% relative to PBS. There was no evidence that the LUB effect was HA-dependent (P = .71).
Synovial Fluid Analyses
No statistically significant differences were observed in urea-adjusted synovial lavage concentrations of sGAG, CTX-II, IL-1b, and TNF-a at the time of harvest ( Table 1 ). The sGAG levels were observed to be lowest in the HA-treated group but overall were similar in all groups. The CTX-II levels were lowest in the group treated with LUB alone, while PBS-and HA-treated subjects had similar elevated levels of CTX-II. The LUB1HA-treated subjects showed intermediate levels of CTX-II. Interleukin-1b was lowest in the HA-treated group. The LUB1HA-and PBS-treated samples had the highest levels of IL-1b. The LUB-treated joints showed intermediate levels of IL-1b. Tumor necrosis factor-a levels were elevated in PBS-treated specimens, and HA-, LUB-, and LUB1HA-treated specimens had similar lower levels of TNF-a. Lubricin levels were significantly higher in the LUB and LUB1HA treatment groups at time of joint harvest compared with the PBS-and HA-treated groups (P = .008) ( Figure 5 ).
DISCUSSION
The results of our study confirm our first hypothesis that intra-articular supplementation with LUB after ACL injury reduces articular cartilage damage as indicated by radiography and histology. However, we were unable to accept our second and third hypotheses since intra-articular supplementation with HA alone did not have an effect, and the addition of HA combined with LUB did not further reduce articular cartilage damage compared with LUB alone. Statistically significant differences in synovial fluid levels of inflammatory mediators and cartilage breakdown products were not seen, possibly due to the multifactorial processes by which posttraumatic cartilage degeneration occurs, the possible lack of a difference at the 6-week time point, the limited sample size, our ability to reproducibly perform the lavages in such a small knee, or other limitations of the rat model. Given that significant differences were present in the histologic and radiologic scores of cartilage damage, and that the LUB concentrations in the synovial fluid of the LUB-treated animals remained elevated 1 week after the final injection, intra-articular supplementation with LUB appears to be a promising approach to minimize the effect of posttraumatic OA in the ACL-deficient knee. However, more study is needed to understand the effects of LUB and HA treatment on the metabolism of articular cartilage over the long term. Anterior cruciate ligament transection has been used previously to induce OA in the rat knee. 12, 18 Using the modified OARSI scale, Hayami et al 18 demonstrated that histological cartilage damage could be detected within 2 weeks of surgery, and would continue to progress over time. Visibly roughened articular surfaces, cartilage defects, and osteophyte formation were present 6 weeks after surgery-the interval selected for this study. Hayami et al concluded that the rat ACL transection model shared many characteristics (ie, progressive cartilage damage, subchondral bone sclerosis, and osteophyte formation) seen in the human and other animal models of OA. 12, 18 As with most animal OA models, arthrosis appears to be accelerated in the ACL-deficient rat knee when compared with the human knee. Although this can be perceived as a limitation, the rat provides a validated model that is small, easy to handle, relatively inexpensive, and responds to both injury and treatment in a timely manner. It is ideal to provide proof of concept and to then design large animal and clinical studies to translate a novel chondroprotective therapy to clinical practice.
The concentration of LUB for the injections used in our study, 200 mg/mL, was based on the level of LUB measured in normal synovial fluid. 24, 27, 45, 54, 55 Of note, purified human LUB was used for injection, rather than native rat LUB, which may introduce the possibility of immunoreactivity and increased cartilage damage. However, our finding of decreased OA progression in the LUB-supplemented joints suggested that this was not the case. Also, the LUB molecule is highly conserved across species, further minimizing this concern. The concentration of HA and molecular weight of HA for the injection protocol in this study was also based on physiologic concentrations. Hyaluronic acid is normally found in high concentrations, 2 to 4 mg/mL, with an average molecular weight of 1 3 10 6 Da. 3, 9, 27 After acute knee injury, synovial fluid levels of LUB are decreased, likely as a consequence of inflammatory degradation, and there is subsequent loss of lubricating ability. 11, 23 It has been shown that patients with camptodactyly arthropathy coxa vara pericarditis (CACP) syndrome, who lack the functional gene for LUB expression, produce synovial fluid that lacks lubricating ability, and hence develop severe precocious arthritis. 26 It has also been shown that the lack of the LUB gene in a mouse model results in increased joint friction and accelerated arthritis progression, 45 that increased joint friction results from brief proteolytic degradation of the mucin layer at the surface of intact joints, 57 and that in late arthritis after ACL transection, low levels of LUB are associated with increased whole-joint friction. 57 These findings lead to the question of whether supplementing the lubricating components of synovial fluid may delay or prevent the progression of posttraumatic OA in the ACL-injured patient, the objective of the present study.
Our findings that intra-articular LUB supplementation reduces radiographic and histologic measures of posttraumatic arthritis are consistent with the data published by Flannery et al, 14 who showed delayed OA progression after intra-articular supplementation using recombinant LUB. In their study, a recombinant form of LUB, containing a shortened central mucin domain, was injected intraarticularly in the rat knee. Osteoarthritis was induced by sectioning the medial meniscus and medial collateral ligament. The rats received recombinant LUB injections either 1 or 3 times per week for 4 weeks after surgery and were matched with saline injection control animals. The outcome measures in their study showed significant reductions in cartilage degeneration scores, total joint scores, widths of severe lesions, and significant cartilage degeneration widths. Their study did not include radiographic or synovial fluid analyses nor did it use a fulllength natural LUB control. 14 In this study, the Kellgren-Lawrence score was selected to evaluate radiographic evidence of cartilage damage. 32 Because the radiographs were taken post mortem, weightbearing radiographs were not obtained so joint-space narrowing was not included in the Kellgren-Lawrence assessment. The modified numerical score corresponded to the following descriptors of OA: none, doubtful, minimal, moderate, and severe. When the assessments were being performed, the evaluators were blinded to the animal and treatment groups. The average of the 2 independent scores (an expert and a novice) were intentionally used to add variability. Despite this, there were significant differences between treatments. Poor reliability between examiners would only undermine the analysis if we did not find differences between groups.
Although HA is thought to contribute to the viscosity of synovial fluid, 27, 31, 39 there has been recent debate about its ability to act as a surface lubricant. 50 A recent study evaluating the ability of HA to interact with idealized bearing surfaces has shown that it does not effectively coat the articulating surfaces, as would be required for boundary lubrication. 7 In addition, synovial fluid treated with hyaluronidase does not lose its lubricating ability, while a All values provided as the mean 6 standard deviation. No significant interaction between LUB and HA was observed for any of these biomarkers (significance not shown). PBS, phosphate-buffered saline; HA, hyaluronic acid; LUB, lubricin; sGAG, sulfated glycosaminoglycan; CTX-II, type II collagen; TNF-a, tumor necrosis factor-a; IL-1b, interleukin-1b. synovial fluid treated with proteases, which would remove LUB, is an ineffective lubricant. 22 Although HA may not be an effective boundary lubricant, it has been shown that LUB alters the mechanical properties of HAcontaining solutions: HA and LUB in solution together to lower viscosity and alter diffusion compared with HAonly solutions. 27 Based on the results of the current study, the combination of HA plus LUB does not appear to be synergistic in preventing cartilage damage, although it should be noted that this may be attributable to the limited sample size, which was only 80% powered to detect a 35% between the mean values. Although significant differences in inflammatory markers (IL-1b, TNF-a) and cartilage breakdown products (CTX-II, sGAG) were not seen in this study, existing data suggest that both HA and LUB may act as signaling molecules in addition to possessing mechanical lubricating properties. Of interest in this study, HA injection had the greatest effect in lowering IL1b, while both LUB-and HA-treated animals had lower levels of TNF-a. The cytokines IL-1b and TNF-a are of importance in cartilage degradation in OA. Interleukin-1b has been found to be spontaneously released by OA cartilage, 2 and both IL-b and TNF-a perpetuate cartilage matrix degradation by stimulating the release of stromelysin (matrix metalloproteinase [MMP]-3), collagenases (MMP-1/8/13), gelatinases (MMP-2/9), and by their own action. 40, 43 It should be noted that the cartilage metabolism biomarker data from this study must be treated with caution because of the relatively small sample size. For these 4 biomarkers, we were only 80% powered to detect a shift of 1 standard deviation between treatments. Furthermore, lavages were only obtained after euthanasia so we do not know what the concentrations of each marker were during the active course of treatment. Further investigations will need to address the metabolic effects of LUB and HA treatment on chondrocyte and synoviocyte metabolism, including their effects on inflammation and enzyme expression.
The progression of OA after injury is multifactorial, and a model in which OA progression occurs more slowly, for example after meniscal injury instead of ACL transection, will be studied in the future to further explore the metabolic effects of tribosupplementation. In addition, interval and longer term follow-up periods will be included to determine if the observed reduction in OA progression persists after treatment. The delay in OA progression after LUB treatment shown in this study did not correlate with significant alterations in inflammatory marker expression, but it is also possible that ongoing mechanical damage, which may have been partially prevented by supplementing the lubricating ability of synovial fluid, was the main contributor to OA progression. Further investigations will focus on the effects of supplemental LUB and HA on the metabolism and mechanical properties of articular cartilage.
